Zotizalkib
Zotizalkib (TPX-0131) is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM) . Zotizalkib has strong antitumor activities[1].
Product Specifications
CAS Number
[2648641-36-3]
Product Name Alternative
TPX-0131
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK)
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zotizalkib.html
Purity
98.02
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
FC([C@H]1N2C3=NC4=C(C(NC(C)(COC5=CC=C(F)C=C5C2)C)=O)C=NN4C=C3OC1)F
Molecular Formula
C21H20F3N5O3
Molecular Weight
447.41
References & Citations
[1]Brion W Murray, et al. TPX-0131, a Potent CNS-Penetrant, Next-Generation Inhibitor of Wild-Type ALK and ALK-Resistant Mutations. Mol Cancer Ther. 2021 Jun 22; molcanther.0221.2021.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
353114 100 µg
VEGFD (c-fos Induced Growth Factor, Vascular Endothelial Growth Factor D, FIGF, VEGF-D)
Sign In for Pricing
View Details ABC-X1493 1 Vial
Xpress™ Human IGSF22 Over-expressing Stable Cell Line
Sign In for Pricing
View Details